- Home
- BMEA vs STRO Comparison
BMEA vs STRO Comparison
Compare BMEA & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- STRO
- Stock Information
- Founded
- BMEA 2017
- STRO 2003
- Country
- BMEA United States
- STRO United States
- Employees
- BMEA N/A
- STRO N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BMEA Health Care
- STRO Health Care
- Exchange
- BMEA Nasdaq
- STRO Nasdaq
- Market Cap
- BMEA 275.6M
- STRO 292.6M
- IPO Year
- BMEA 2021
- STRO 2018
- Fundamental
- Price
- BMEA $6.38
- STRO $2.53
- Analyst Decision
- BMEA Buy
- STRO Strong Buy
- Analyst Count
- BMEA 13
- STRO 7
- Target Price
- BMEA $37.25
- STRO $12.14
- AVG Volume (30 Days)
- BMEA 814.9K
- STRO 813.4K
- Earning Date
- BMEA 10-29-2024
- STRO 11-13-2024
- Dividend Yield
- BMEA N/A
- STRO N/A
- EPS Growth
- BMEA N/A
- STRO N/A
- EPS
- BMEA N/A
- STRO N/A
- Revenue
- BMEA N/A
- STRO $160,955,000.00
- Revenue This Year
- BMEA N/A
- STRO N/A
- Revenue Next Year
- BMEA N/A
- STRO N/A
- P/E Ratio
- BMEA N/A
- STRO N/A
- Revenue Growth
- BMEA N/A
- STRO 230.90
- 52 Week Low
- BMEA $3.61
- STRO $2.13
- 52 Week High
- BMEA $22.74
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- BMEA 24.23
- STRO 28.23
- Support Level
- BMEA $6.04
- STRO $2.60
- Resistance Level
- BMEA $9.34
- STRO $4.60
- Average True Range (ATR)
- BMEA 0.54
- STRO 0.36
- MACD
- BMEA -0.26
- STRO -0.16
- Stochastic Oscillator
- BMEA 10.30
- STRO 0.48
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.